Skip to main content
Erschienen in: Cellular Oncology 6/2015

01.12.2015 | Original Paper

The carboxy-terminal domain of connexin 43 (CT-Cx43) modulates the expression of p53 by altering miR-125b expression in low-grade human breast cancers

verfasst von: Raihana Maqbool, Rabiya Rashid, Rehana Ismail, Saif Niaz, Nisar Ahmad Chowdri, Mahboob Ul Hussain

Erschienen in: Cellular Oncology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Connexin 43 (Cx43) is a widely expressed gap junction protein. It can also regulate various gap-junction independent processes, including cellular proliferation. The latter regulatory functions have been attributed to its carboxy-terminal domain, CT-Cx43. CT-Cx43 has been found to be expressed independent of full-length Cx43 in various cell types. Its nuclear localization has additionally raised the possibility that it may regulate the expression of particular genes, including miRNAs, known play a role in the regulation of cellular proliferation. Here, we set out to uncover the molecular mechanism(s) underlying CT-Cx43 mediated gene (de-)regulation in human breast cancer.

Methods

Western blotting and quantitative real time PCR were carried to assess the expression of CT-Cx43 and miR-125b in a panel of 60 primary human breast cancer tissues and its paired normal adjacent tissues. In addition, CT-Cx43 was exogenously expressed in the breast cancer-derived cell line MCF-7 and its effect on the expression of miR-125b and its downstream target p53 were evaluated, as well as its effect on cellular proliferation and death using MTT and LDH assays, respectively.

Results

We found that CT-Cx43, but not full-length Cx43, was down-regulated in low grade human breast cancers. In addition, we found that the tumor suppressor protein p53 exhibited a decreased expression in the CT-Cx43 down-regulated samples. Interestingly, we found that miR-125b, a negative regulator of p53, exhibited an inverse expression relationship with CT-Cx43 in the breast cancer samples tested. This inverse relationship was confirmed by exogenous expression of CT-Cx43 in MCF-7 cells. In addition, we found that CT-Cx43 up-regulation and subsequent miR-125b down-regulation resulted in a decreased proliferation of MCF-7 cells.

Conclusions

Our data suggest a mechanism by which CT-Cx43 may regulate cell proliferation. Targeting of CT-Cx43 and/or miR-125b may be instrumental for therapeutic intervention in human breast cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat G. Mese, G. Richard, T.W. White, Gap junctions: basic structure and function. J. Investig. Dermatol. 127, 2516–2524 (2007)CrossRefPubMed G. Mese, G. Richard, T.W. White, Gap junctions: basic structure and function. J. Investig. Dermatol. 127, 2516–2524 (2007)CrossRefPubMed
2.
Zurück zum Zitat H.A. Dbouk, R.M. Mroue, M.E. El-Sabban, R.S. Talhouk, Connexins: a myriad of functions extending beyond assembly of gap junction channels, Cell. Commun. Signals 7, 4 (2009) H.A. Dbouk, R.M. Mroue, M.E. El-Sabban, R.S. Talhouk, Connexins: a myriad of functions extending beyond assembly of gap junction channels, Cell. Commun. Signals 7, 4 (2009)
3.
Zurück zum Zitat K. Willecke, J. Eiberger, J. Degen, D. Eckardt, A. Romualdi, M. Guldenagel, U. Deutsch, G. Sohl, Structural and functional diversity of connexin genes in the mouse and human genome. Biol. Chem. 383, 725–737 (2002)CrossRefPubMed K. Willecke, J. Eiberger, J. Degen, D. Eckardt, A. Romualdi, M. Guldenagel, U. Deutsch, G. Sohl, Structural and functional diversity of connexin genes in the mouse and human genome. Biol. Chem. 383, 725–737 (2002)CrossRefPubMed
4.
Zurück zum Zitat G. Pointis, J. Gilleron, D. Carette, D. Segretain, Physiological and physiopathological aspects of connexins and communicating gap junctions in spermatogenesis, philosophical transactions of the royal society of london. Series B, Biol. Sci. 365, 1607–1620 (2010) G. Pointis, J. Gilleron, D. Carette, D. Segretain, Physiological and physiopathological aspects of connexins and communicating gap junctions in spermatogenesis, philosophical transactions of the royal society of london. Series B, Biol. Sci. 365, 1607–1620 (2010)
5.
Zurück zum Zitat S. Sirnes, J. Bruun, M. Kolberg, A. Kjenseth, G.E. Lind, A. Svindland, A. Brech, A. Nesbakken, R.A. Lothe, E. Leithe, E. Rivedal, Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome. Int. J. Cancer 131, 570–581 (2012)CrossRefPubMed S. Sirnes, J. Bruun, M. Kolberg, A. Kjenseth, G.E. Lind, A. Svindland, A. Brech, A. Nesbakken, R.A. Lothe, E. Leithe, E. Rivedal, Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome. Int. J. Cancer 131, 570–581 (2012)CrossRefPubMed
6.
Zurück zum Zitat M. Oyamada, Y. Oyamada, T. Takamatsu, Regulation of connexin expression. Biochim. Bophys. Acta 1719, 6–23 (2005)CrossRef M. Oyamada, Y. Oyamada, T. Takamatsu, Regulation of connexin expression. Biochim. Bophys. Acta 1719, 6–23 (2005)CrossRef
7.
Zurück zum Zitat R. Ismail, R. Rashid, K. Andrabi, F.Q. Parray, S. Besina, M.A. Shah, M. Ul Hussain, Pathological implications of Cx43 down-regulation in human colon cancer. Asian Pac. J. Cancer Prev. 15, 2987–2991 (2014)CrossRefPubMed R. Ismail, R. Rashid, K. Andrabi, F.Q. Parray, S. Besina, M.A. Shah, M. Ul Hussain, Pathological implications of Cx43 down-regulation in human colon cancer. Asian Pac. J. Cancer Prev. 15, 2987–2991 (2014)CrossRefPubMed
8.
Zurück zum Zitat C. Moorby, M. Patel, Dual functions for connexins: Cx43 regulates growth independently of gap junction formation. Exp. Cell Res. 271, 238–248 (2001)CrossRefPubMed C. Moorby, M. Patel, Dual functions for connexins: Cx43 regulates growth independently of gap junction formation. Exp. Cell Res. 271, 238–248 (2001)CrossRefPubMed
9.
Zurück zum Zitat J.E. Trosko, R.J. Ruch, Gap junctions as targets for cancer chemoprevention and chemotherapy. Curr. Drug Targets 3, 465–482 (2002)CrossRefPubMed J.E. Trosko, R.J. Ruch, Gap junctions as targets for cancer chemoprevention and chemotherapy. Curr. Drug Targets 3, 465–482 (2002)CrossRefPubMed
10.
Zurück zum Zitat X. Dang, B.W. Doble, E. Kardami, The carboxy-tail of connexin-43 localizes to the nucleus and inhibits cell growth. Mol. Cell. Biochem. 242, 35–38 (2003)CrossRefPubMed X. Dang, B.W. Doble, E. Kardami, The carboxy-tail of connexin-43 localizes to the nucleus and inhibits cell growth. Mol. Cell. Biochem. 242, 35–38 (2003)CrossRefPubMed
11.
12.
Zurück zum Zitat E. Wawryk-Gawda, P. Chylinska-Wrzos, M. Lis-Sochocka, K. Chlapek, K. Bulak, M. Jedrych, B. Jodlowska-Jedrych, P53 protein in proliferation, repair and apoptosis of cells. Protoplasma 251, 525–533 (2014)PubMedCentralCrossRefPubMed E. Wawryk-Gawda, P. Chylinska-Wrzos, M. Lis-Sochocka, K. Chlapek, K. Bulak, M. Jedrych, B. Jodlowska-Jedrych, P53 protein in proliferation, repair and apoptosis of cells. Protoplasma 251, 525–533 (2014)PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat L.A. Voutsadakis, The chemosensitivity of testicular germ cell tumors. Cell. Oncol. 37, 79–94 (2014)CrossRef L.A. Voutsadakis, The chemosensitivity of testicular germ cell tumors. Cell. Oncol. 37, 79–94 (2014)CrossRef
14.
Zurück zum Zitat V.S. Bielicka, P. Domagala, D. Bielicki, K. Safranow, W. Domagala, Thymidylate synthase expression and P21WAF1/P53 phenotype of colon cancers identify patients who may benefit from 3-flurouracil based therapy. Cell. Oncol. 37, 17–28 (2014)CrossRef V.S. Bielicka, P. Domagala, D. Bielicki, K. Safranow, W. Domagala, Thymidylate synthase expression and P21WAF1/P53 phenotype of colon cancers identify patients who may benefit from 3-flurouracil based therapy. Cell. Oncol. 37, 17–28 (2014)CrossRef
15.
Zurück zum Zitat N. Almog, V. Rotter, Involvement of p53 in cell differentiation and development. Biochim. Biophys. Acta 1333, F1–27 (1997)PubMed N. Almog, V. Rotter, Involvement of p53 in cell differentiation and development. Biochim. Biophys. Acta 1333, F1–27 (1997)PubMed
16.
Zurück zum Zitat A.J. Giaccia, M.B. Kastan, The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12, 2973–2983 (1998)CrossRefPubMed A.J. Giaccia, M.B. Kastan, The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12, 2973–2983 (1998)CrossRefPubMed
17.
Zurück zum Zitat K. Sakaguchi, J.E. Herrera, S. Saito, T. Miki, M. Bustin, A. Vassilev, C.W. Anderson, E. Appella, DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12, 2831–2841 (1998)PubMedCentralCrossRefPubMed K. Sakaguchi, J.E. Herrera, S. Saito, T. Miki, M. Bustin, A. Vassilev, C.W. Anderson, E. Appella, DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12, 2831–2841 (1998)PubMedCentralCrossRefPubMed
18.
19.
Zurück zum Zitat L. Zheng, J.Q. Ren, H. Li, Z.L. Kong, H.G. Zhu, Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy. Cell Res. 14, 497–506 (2004)CrossRefPubMed L. Zheng, J.Q. Ren, H. Li, Z.L. Kong, H.G. Zhu, Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy. Cell Res. 14, 497–506 (2004)CrossRefPubMed
20.
Zurück zum Zitat N. Rivlin, R. Brosh, M. Oren, V. Rotter, Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2, 466–474 (2011)PubMedCentralCrossRefPubMed N. Rivlin, R. Brosh, M. Oren, V. Rotter, Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2, 466–474 (2011)PubMedCentralCrossRefPubMed
21.
22.
Zurück zum Zitat M. Ul Hussain, Micro-RNAs (miRNAs): genomic organisation, biogenesis and mode of action. Cell Tissue Res. 349, 405–413 (2012)CrossRefPubMed M. Ul Hussain, Micro-RNAs (miRNAs): genomic organisation, biogenesis and mode of action. Cell Tissue Res. 349, 405–413 (2012)CrossRefPubMed
23.
Zurück zum Zitat R. Maqbool, M. Ul Hussain, MicroRNAs and human diseases: diagnostic and therapeutic potential. Cell Tissue Res. 358, 1–15 (2014)CrossRefPubMed R. Maqbool, M. Ul Hussain, MicroRNAs and human diseases: diagnostic and therapeutic potential. Cell Tissue Res. 358, 1–15 (2014)CrossRefPubMed
24.
Zurück zum Zitat R. Nagadia, P. Pandit, W.B. Coman, J.C. White, C. Punyadeera, MicroRNAs in head and neck cancer revisited. Cell. Oncol. 36, 1–7 (2013)CrossRef R. Nagadia, P. Pandit, W.B. Coman, J.C. White, C. Punyadeera, MicroRNAs in head and neck cancer revisited. Cell. Oncol. 36, 1–7 (2013)CrossRef
25.
Zurück zum Zitat Y. Wang, M. Li, W. Zang, Y. Ma, N. Wang, P. Li, G. Zhao, MiR-429 upregulation induces apoptosis and suppresses invasion by targeting Bcl-2 and SP-1 in esophageal carcinoma. Cell. Oncol. 36, 385--394 (2013)CrossRef Y. Wang, M. Li, W. Zang, Y. Ma, N. Wang, P. Li, G. Zhao, MiR-429 upregulation induces apoptosis and suppresses invasion by targeting Bcl-2 and SP-1 in esophageal carcinoma. Cell. Oncol. 36, 385--394 (2013)CrossRef
26.
Zurück zum Zitat L. Rask, E. Balslev, R. Sokilde, E. Hogdall, H. Flyger, J. Eriksen, T. Litman, Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub classified according to lymph node status. Cell. Oncol. 37, 215–227 (2014)CrossRef L. Rask, E. Balslev, R. Sokilde, E. Hogdall, H. Flyger, J. Eriksen, T. Litman, Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub classified according to lymph node status. Cell. Oncol. 37, 215–227 (2014)CrossRef
27.
Zurück zum Zitat C. Salazar, R. Nagadia, P. Pandit, J.C. White, N. Banerjee, N. Dimitrova, W.B. Coman, C. Pundyadeera, A novel saliva based microRNA biomarker panel to detect head and neck cancers. Cell. Oncol. 37, 331–338 (2014)CrossRef C. Salazar, R. Nagadia, P. Pandit, J.C. White, N. Banerjee, N. Dimitrova, W.B. Coman, C. Pundyadeera, A novel saliva based microRNA biomarker panel to detect head and neck cancers. Cell. Oncol. 37, 331–338 (2014)CrossRef
28.
29.
Zurück zum Zitat C. Chen, D.A. Ridzon, A.J. Broomer, Z. Zhou, D.H. Lee, J.T. Nguyen, M. Barbisin, N.L. Xu, V.R. Mahuvakar, M.R. Andersen, K.Q. Lao, K.J. Livak, K.J. Guegler, Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33, e179 (2005)PubMedCentralCrossRefPubMed C. Chen, D.A. Ridzon, A.J. Broomer, Z. Zhou, D.H. Lee, J.T. Nguyen, M. Barbisin, N.L. Xu, V.R. Mahuvakar, M.R. Andersen, K.Q. Lao, K.J. Livak, K.J. Guegler, Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33, e179 (2005)PubMedCentralCrossRefPubMed
30.
Zurück zum Zitat M. Ul-Hussain, S. Olk, B. Schoenebeck, B. Wasielewski, C. Meier, N. Prochnow, C. May, S. Galozzi, K. Marcus, G. Zoidl, R. Dermietzel, Internal ribosomal entry site (IRES) activity generates endogenous carboxyl-terminal domains of Cx43 and is responsive to hypoxic conditions. J. Biol. Chem. 289, 20979–20990 (2014) M. Ul-Hussain, S. Olk, B. Schoenebeck, B. Wasielewski, C. Meier, N. Prochnow, C. May, S. Galozzi, K. Marcus, G. Zoidl, R. Dermietzel, Internal ribosomal entry site (IRES) activity generates endogenous carboxyl-terminal domains of Cx43 and is responsive to hypoxic conditions. J. Biol. Chem. 289, 20979–20990 (2014)
31.
Zurück zum Zitat N. Wu, X. Lin, X. Zhao, L. Zheng, L. Xiao, J. Liu, L. Ge, S. Cao, MiR-125b acts as an oncogene in glioblastoma cells and inhibits cell apoptosis through p53 and p38MAPK-independent pathways. Br. J. Cancer 109, 2853–2863 (2013) N. Wu, X. Lin, X. Zhao, L. Zheng, L. Xiao, J. Liu, L. Ge, S. Cao, MiR-125b acts as an oncogene in glioblastoma cells and inhibits cell apoptosis through p53 and p38MAPK-independent pathways. Br. J. Cancer 109, 2853–2863 (2013)
32.
Zurück zum Zitat A. Feliciano, J. Castellvi, A. Artero-Castro, J.A. Leal, C. Romagosa, J. Hernandez-Losa, V. Peg, A. Fabra, F. Vidal, H. Kondoh, Y.C.S. Ramon, M.E. Lleonart, miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-alpha, CCNJ, and MEGF9. PLoS One 8, e76247 (2013)PubMedCentralCrossRefPubMed A. Feliciano, J. Castellvi, A. Artero-Castro, J.A. Leal, C. Romagosa, J. Hernandez-Losa, V. Peg, A. Fabra, F. Vidal, H. Kondoh, Y.C.S. Ramon, M.E. Lleonart, miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-alpha, CCNJ, and MEGF9. PLoS One 8, e76247 (2013)PubMedCentralCrossRefPubMed
33.
Zurück zum Zitat A. Geurts van Kessel, The cancer genome: from structure to function. Cell. Oncol. 37, 155–165 (2014) A. Geurts van Kessel, The cancer genome: from structure to function. Cell. Oncol. 37, 155–165 (2014)
34.
Zurück zum Zitat H.J. Wang, Y.Q. Guo, G. Tan, L. Dong, L. Cheng, K.J. Li, Z.Y. Wang, H.F. Luo, miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype, J.Cell. Biochem. 114, 2248–2257 (2013) H.J. Wang, Y.Q. Guo, G. Tan, L. Dong, L. Cheng, K.J. Li, Z.Y. Wang, H.F. Luo, miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype, J.Cell. Biochem. 114, 2248–2257 (2013)
35.
Zurück zum Zitat H. Wang, G. Tan, L. Dong, L. Cheng, K. Li, Z. Wang, H. Luo, Circulating MiR-125b as a marker predicting chemoresistance in breast cancer, PloS One.7, e34210 (2012) H. Wang, G. Tan, L. Dong, L. Cheng, K. Li, Z. Wang, H. Luo, Circulating MiR-125b as a marker predicting chemoresistance in breast cancer, PloS One.7, e34210 (2012)
36.
Zurück zum Zitat D.A. Iacobas, E. Scemes, D.C. Spray, Gene expression alterations in connexin null mice extend beyond the gap junction. Neurochem. Int. 45, 243–250 (2004)CrossRefPubMed D.A. Iacobas, E. Scemes, D.C. Spray, Gene expression alterations in connexin null mice extend beyond the gap junction. Neurochem. Int. 45, 243–250 (2004)CrossRefPubMed
37.
Zurück zum Zitat E. Kardami, X. Dang, D.A. Iacobas, B.E. Nickel, M. Jeyaraman, W. Srisakuldee, J. Makazan, S. Tanguy, D.C. Spray, The role of connexins in controlling cell growth and gene expression. Prog. Biophys. Mol. Biol. 94, 245–264 (2007)CrossRefPubMed E. Kardami, X. Dang, D.A. Iacobas, B.E. Nickel, M. Jeyaraman, W. Srisakuldee, J. Makazan, S. Tanguy, D.C. Spray, The role of connexins in controlling cell growth and gene expression. Prog. Biophys. Mol. Biol. 94, 245–264 (2007)CrossRefPubMed
38.
Zurück zum Zitat M. Hollstein, D. Sidransky, B. Vogelstein, C.C. Harris, p53 mutations in human cancers. Science 253, 49–53 (1991)CrossRefPubMed M. Hollstein, D. Sidransky, B. Vogelstein, C.C. Harris, p53 mutations in human cancers. Science 253, 49–53 (1991)CrossRefPubMed
39.
Zurück zum Zitat U.M. Moll, G. Riou, A.J. Levine, Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. U. S. A. 89, 7262–7266 (1992)PubMedCentralCrossRefPubMed U.M. Moll, G. Riou, A.J. Levine, Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. U. S. A. 89, 7262–7266 (1992)PubMedCentralCrossRefPubMed
Metadaten
Titel
The carboxy-terminal domain of connexin 43 (CT-Cx43) modulates the expression of p53 by altering miR-125b expression in low-grade human breast cancers
verfasst von
Raihana Maqbool
Rabiya Rashid
Rehana Ismail
Saif Niaz
Nisar Ahmad Chowdri
Mahboob Ul Hussain
Publikationsdatum
01.12.2015
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 6/2015
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-015-0240-x

Weitere Artikel der Ausgabe 6/2015

Cellular Oncology 6/2015 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …